Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 366 • 2012 ACR/ARHP Annual Meeting
Efficacy of Methotrexate (MTX) According to Anti-Citrullinated Protein Antibody (ACPA) Status in an Early Inflammatory Arthritis Cohort
Sarah C. Horton¹, David Pickles¹, Paul Emery¹, Maya H. Buch² and Jane E. Freeston¹, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Data suggests patients with early, ACPA negative, rheumatoid (RA) and undifferentiated arthritis (UA) are less likely to achieve remission with MTX at 4 months…
Abstract Number: 348 • 2012 ACR/ARHP Annual Meeting
Liver Fibrosis Evaluated by Shearwave Elastograpy Is Associated with Body Mass Index and Serum AST, but Not Methotrexate Cumulative Dose and Duration in Patients with Rheumatoid Arthritis
Tae Yeob Kim¹, So-Young Bang², Joo Hyun Sohn³ and Hye-Soon Lee², ¹Gastroenterology, Hanyang University Guri Hospital, Guri, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Hanyang University Guri Hospital, Guri, South Korea
Background/Purpose: Methotrexate (MTX) is a widely used drug for treatment of rheumatoid arthritis (RA), and a concern with drug-related liver fibrosis is an unsolved problem.…
Abstract Number: 2640 • 2012 ACR/ARHP Annual Meeting
Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Gail S. Kerr⁴, Andreas M. Reimold⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the most commonly used medication for patients with rheumatoid arthritis (RA), however, the frequency of MTX adverse events (AE) has not…
Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting
Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Aase Haj Hensvold¹, Saedis Saevarsdottir*², Wanyiang Li*³, Vivianne Malmström⁴, Guy Cavet⁵, Lars Klareskog⁶ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
*equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
Abstract Number: 1821 • 2012 ACR/ARHP Annual Meeting
Clinical Predictors of Methotrexate-Induced Liver Enzyme Elevation in Patients with Rheumatoid Arthritis in an Electronic Medical Record
Monica Ramirez¹, Bing Lu¹, Michelle A. Frits², Anne H. Fossel³, Katherine P. Liao⁴, Robert M. Plenge⁵, Jonathan S. Coblyn⁶, Nancy A. Shadick⁷ and Elizabeth W. Karlson⁴, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham & Womens Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Methotrexate (MTX) use for the treatment of rheumatoid arthritis (RA) has been associated with hepatotoxicity, and requires monitoring of liver transaminases. However, elevations in…
Abstract Number: 1838 • 2012 ACR/ARHP Annual Meeting
10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study
Bernard Ng¹, Nancy Petersen², Hong-Jen Yu², Myrna Khan² and Maria E. Suarez-Almazor³, ¹Dept of Rheumatology, Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, ²Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, ³The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: It is unclear how recommendations for disease modifying anti-rheumatic drugs (DMARDs) & biological agents in treatment of Rheumatoid Arthritis (RA) have influenced their use…
Abstract Number: 1317 • 2012 ACR/ARHP Annual Meeting
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Janet E. Pope¹, Boulos Haraoui², J. Carter Thorne³, Melanie Poulin-Costello⁴, Andrew Vieira⁵ and Edward Keystone⁶, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Combination therapy with a biologic and methotrexate (MTX) usually yields better outcomes than biologic monotherapy in rheumatoid arthritis (RA).1,2,3 However, patients may be intolerant…
Abstract Number: 1304 • 2012 ACR/ARHP Annual Meeting
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Edward Keystone¹, Ferdinand C. Breedveld², Hartmut Kupper³, Shufang Liu⁴ and Stefan Florentinus⁵, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁴Immunology Development, Abbott, Abbott Park, IL, ⁵AbbVie, Rungis, France
Background/Purpose: There has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical…
Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Roy Fleischmann¹, Andrew S. Koenig², Annette Szumski³, Henk Nab⁴, Lisa Marshall⁵ and Eustratios Bananis³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Europe, Rome, Italy, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…
Abstract Number: 364 • 2012 ACR/ARHP Annual Meeting
Moderate Rheumatoid Arthritis Despite Methotrexate Treatment: Risk of Radiographic Progression
Bruno Fautrel¹, Gaia Gallo², Yves Brault³ and Henk Nab², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Pfizer Europe, Rome, Italy, ³Pfizer, Paris, France
Background/Purpose: Clinical remission or low disease activity are the main goals of rheumatoid arthritis (RA) treatment and European League Against Rheumatism guidelines recommend switching treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].